Dose de‐escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease – a nested case–control study
S. Van Steenbergen; S. Bian; S. Vermeire; G. Van Assche; A. Gils; M. Ferrante
Author Information: Department of General Practice
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.